<DOC>
	<DOCNO>NCT02460731</DOCNO>
	<brief_summary>This phase 1 , multi-center , open-label study safety , tolerability , pharmacodynamics , preliminary efficacy young ( &lt; 30 year age ) healthy male donor plasma transfusion patient PSP . Up 10 subject receive monthly 4-unit transfusion young healthy male donor plasma 6 month .</brief_summary>
	<brief_title>Young Plasma Transfusions Progressive Supranuclear Palsy</brief_title>
	<detailed_description>This phase 1 , multi-center , open-label study safety , tolerability , pharmacodynamics , preliminary efficacy young ( &lt; 30 year age ) healthy male donor plasma transfusion patient PSP . Up 10 subject receive monthly 4-unit transfusion young healthy male donor plasma 6 month . If ≥3 subject experience drug limit toxicity ( DLT ) , define Section 7.19 , study terminate . Any subject experience DLT discontinue treatment study drug . An interim futility analysis perform five subject complete 6 month study drug treatment . If criterion list Section 9.3 protocol meet , additional 5 subject enrol trial . If , trial terminate .</detailed_description>
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<criteria>1 . Meets National Institute Neurological Disorders Stroke Society Progressive Supranuclear Palsy ( NINDSSPSP ) probable possible PSP criterion ( Litvan et al . 1996b ) , modify AL108231 davunetide trial ( Boxer et al . 2014 ) ; 2 . Between 50 85 year age ( inclusive ) ; 3 . MRI Screening consistent PSP ( ≤ 4 microhemorrhages large stroke severe white matter disease ) ; 4 . MMSE score Screening 14 30 ( inclusive ) ; 5 . Stable medication 2 month prior Screening , include Food Drug Administration ( FDA ) approve Alzheimer 's disease ( AD ) medication Parkinson 's disease medication ; 6 . Availability study partner know subject well willing accompany subject trial visit participate questionnaire ; 7 . Agrees 3 MRIs ; 8 . Agrees 2 lumbar puncture CSF examination ; 9 . Signed date write informed consent obtain subject subject 's caregiver accordance local IRB regulation ; 10 . Males WCBP agree abstain sex use adequate method contraception duration study 30 day last dose study drug . Adequate contraceptive method include low failure rate , i.e. , less 1 % per year , use consistently correctly , complete abstinence sexual intercourse potentially fertile partner , double barrier method ( condom spermicide ) conjunction use partner intrauterine device ( IUD ) , diaphragm spermicide , oral contraceptive , birth control patch vaginal ring , oral , injectable implanted contraceptive ; For study , woman surgically sterilize state amenorrhea two year deem childbearing potential . 1 . Meets National Institute AgingAlzheimer 's Association Workgroups criterion probable AD ( McKhann et al . 2011 ) ; 2 . Any medical condition PSP could account cognitive deficit ( e.g. , active seizure disorder , stroke , vascular dementia ) ; 3 . A prominent sustain response levodopa therapy ; 4 . History significant cardiovascular , hematologic , renal , hepatic disease ( laboratory evidence thereof ) ; 5 . History major psychiatric illness untreated depression ; 6 . Neutrophil count &lt; 1,500/mm3 , platelet &lt; 100,000/mm3 , serum creatinine &gt; 1.5 x upper limit normal ( ULN ) , total bilirubin &gt; 1.5 x ULN , alanine aminotransferase ( ALT ) &gt; 3 x ULN , aspartate aminotransferase ( AST ) &gt; 3 x ULN , INR &gt; 1.2 Screening evaluation ; 7 . Evidence clinically significant finding Screening baseline evaluation , opinion Investigator would pose safety risk interfere appropriate interpretation study data ; 8 . Current recent history ( within four week prior Screening ) clinically significant bacterial , fungal , mycobacterial infection ; 9 . Current clinically significant viral infection ; 10 . Major surgery within four week prior Screening ; 11 . Any contraindication unable tolerate lumbar puncture Screening , include use anticoagulant medication warfarin . Daily administration 81 mg aspirin allow long dose stable 30 day prior Screening ; 12 . Any contraindication monthly plasma transfusion , include limited : . History significant transfusion complication ; b . Lack competent adult home summon medical assistance need ; c. Lack telephone contact emergency personnel lack easy access emergency vehicle ; d. Compatible plasma unit available ; e. Prior intolerance intravenous ( IV ) fluid ; f. IgA deficiency history laboratory evidence Screening ; g. Uremia bleeding ; h. Any concurrent use anticoagulant therapy . Daily administration 81 mg aspirin allow long dose stable 30 day prior Screening . Antiplatelet drug acceptable . 13 . Treatment another investigational drug participation another interventional clinical trial within 3 month Screening ; 14 . Treatment human blood product , include IV immunoglobulin , 6 month prior Screening trial ; 15 . Pregnant lactating ; 16 . Positive pregnancy test Screening Baseline ( Day 1 ) ; 17 . Cancer within 5 year Screening , except nonmetastatic skin cancer nonmetastatic prostate cancer expect cause significant morbidity mortality within one year Baseline .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>PSP</keyword>
	<keyword>Young Plasma</keyword>
</DOC>